Management of severe candidal infections: Integration and review of current guidelines for treatment and prevention

Current Clinical Topics in Infectious Diseases

Volumn , Issue 21, 2001, Pages 135-147

  Edwards Jr , John E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT;

CANDIDIASIS; HUMAN; PRACTICE GUIDELINE; REVIEW;

ANTIFUNGAL AGENTS; CANDIDIASIS; HUMANS; PRACTICE GUIDELINES;

EID: 0035231957     PISSN: 01953842     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (118)

1. Edwards JEJ, Filler SG. Current strategies for treating invasive candidiasis: emphasis on infections in nonneutropenic patients. Clin Infect Dis 1992;14(suppl 1):S106-S113.
2. Swerdloff JN, Filler SG, Edwards JEJ. Severe candidal infections in netitropenic patients. Clin Infect Dis 1993;17(suppl 2):S457-S467.
3. Edwards JE Jr, Bodey GP, Bowden RA, et al. International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections [see comments]. Clin Infect Dis 1997;25:43-59.
4. Rex JEI, Walsh TJ, Sobel JD, et al. Treatment guidelines for candidiasis. Clin Infect Dis 2000;12:1-10.
5. Wey SB, Mori M, Pfaller MA, et al. Hospitalacquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 1988; 148:2642-26-45.
6. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fiuconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-1330.
7. Anaissie EJ, Rex JII, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med 1998;104:238-245.
8. Nguyen MH, Peacock JE Jr, Tanner DC, et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med 1995; 155;2429-2435.
9. Phillips P, Shafran S, Garber G, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis 1997;16:337-345.
10. Fichtenbaum CJ, German M, Dunagan WC, et al. A pilot study of the management of uncomplicated candidemia with a standardized protocol of amphotericin B. Clin Infect Dis 1999;29: 1551-1556.
11. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agent Chemother 1995;39:1-8.
12. Rex JH. Editorial response: catheters and candidemia. Clin Infect Dis 1996;22:467-470.
13. Rex JH, Bennett JE, Sugar AM, et al. Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin Infect Dis 1995;21:994-996.
14. Wise GJ, Silver DA. Fungal infections of the genitourinary system. 1993;149:1377-1388.
15. Sobel JD, Kauffman CA, McKinscy D, et al. Candiduria: a randomized, double-blind study of treatment with flucomzole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 2000;30:19-24.
16. Kauffman CA, Vazquez JA, Sobel JD, et al. Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 2000; 30:14-18.
17. Taylor GD, Buchanan-Chell M, Kirkland T, et al. Trends and sources of nosocomial fungemia. 1994;37:187-190.
18. Nassoura Z, Ivatury RR, Simon RJ, et al. Candiduria as an early marker of disseminated infection in critically ill surgical patients: the role of fluconazole therapy. J Trauma 1993;35: 290-294.
19. Gubbins PO, Piscitelli SC, Danziger LH. Candidal urinary tract infections: a comprehensive review of their diagnosis and management. Pharmacotherapy 1993;B:110-127.
20. Ang BS, Telenti A, King B, et al. Candidemia from a urinary tract source: microbiological aspects and clinical significance. Clin Infect Dis 1993;17:662-666.
21. Sanford JP. The enigma of candiduria: Evolution of bladder irrigation with aniphotericin B for management - from anecdote to dogma and a lesson from Machiavelli. Clin Infect Dis 1993; 16:145-147.
22. Voss A, Meis JF, Hoogkamp-Korstanje JA. Fluconazole in the management of fungal urinary tract infections. Infection 1994;22:247-251.
23. Troke PF. Large-scale multicenter study of fluconazole in the treatment of hospitalized patients with fungal infections. Multicenter European Study Group. Eur J Clin Microbiol Infect Dis 1997;16:287-295.
24. Francis P, Walsh TJ. Evolving role of flucytosine in immunocoinpromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis 1992;15:1003-1018.
25. Haron E, Vartivarian S, Anaissie E, et al. Primary Candida pneumonia: Experience at a large cancer center and review of the literature. Medicine (Baltimore) 1993;72:137-142.
26. Masur H, Rosen PP, Armstrong D. Pulmonary disease caused by Candida species. Am J Med 1977;63:914-925.
27. el-Ebiary M, Tones A, Fabregas N, et al. Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients. An immediate postmortem histologic study. Am J Respir Crit Care Med 1997;156:583-590.
28. Rello J, Esandi ME, Diaz E, et al. The role of Candida sp isolated from bronchoscopic samples in nonneutropenic patients. Chest 1998;114: 146-149.
29. Connolly JE Jr, McAdams HP, Erasmus JJ, Rosado-de-Christenson ML. Opportunistic fungal pneumonia. J Thoracic Imaging 1999;14: 51-62.
30. Calandra T, Bille J, Schneider R, et al. Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet 1989;2: 1437-1440.
31. Solomkin JS, Flohr AB, Quie PG, et al. The role of Candida in intraperitoneal infections. Surgery 1980;88:524-530.
32. Chan TM, Chan CY, Cheng SW, et al. Treatment of fungal peritonitis complicating continuous ambulatory peritoneal dialysis with oral flnconazole: a series of 21 patients [see comments]. Nephrol Dial Transp 1994;9:539-542.
33. Abraham G, Vas SI. Treatment of fungal peritonitis in patients undergoing continuous ambulatory peritoneal dialysis [letter; comment]. Am J Med 1990;88:699-700.
34. Amici G, Grandesso S, Mottola A, et al. Fungal peritonitis in peritoneal dialysis: critical review of six cases. Adv Perit Dial 1994;10:169-173.
35. Eisenberg ES, Leviton I, Soeiro R. Fungal peritonitis in patients receiving peritoneal dialysis: experience with 11 patients and review of the literature [published erratum appears in Rev Infect Dis 1986;8:839]. Rev Infect Dis 1986;8: 309-321.
36. Huang TC, Cluing WK. Fluconazole in the treatment of Candida peritonitis in continuous ambulatory peritoneal dialysis: report of a case. J Formos Med Asso 1993;92:190-191.
37. Levine J, Bernard DB, Idelson BA, et al. Fungal peritonitis complicating continuous ambulatory peritoneal dialysis: successful treatment with fluconazole, a new orally active antifungal agent [see comments]. Am J Med 1989;86:825-827.
38. Montenegro J, Aguirre R, Gonzalez O, et al. Fluconazole treatment of Candida peritonitis with delayed removal of the peritoneal dialysis catheter. Clin Nephrol 1995;44:60-63.
39. Rodriguez-Perez JC. Fungal peritonitis in CAPD - which treatment is best? Contrib Nephrol 1987;57:114-121.
40. Diebel LN, Raafat MI, Dulchavsky SA, Brown WJ. Gallbladder and biliary tract candidiasis. Surgery 1996;120:760-764.
41. Bozzette SA, Gordon RL, Yen A, et al. Biliary concentrations of flueonazole in a patient with candidat cholecystitis: case report. Clin Infect Dis 1992;15:701-703.
42. Adamson PC, Rinaldi MG, Pizzo PA, Walsh TJ. Amphotericin B in the treatment of Candida cholecystitis. 1989;8:408-411.
43. Morris AB, Sands ML, Shiraki M, et al. Gallbladder and biliary tract candidiasis: nine cases and review [see comments]. Rev Infect Dis 1990;12:483-489.
44. Howard JM, Bieluch VM. Pancreatic abscess secondary to Candida albicans. Pancreas 1989; 4:120-122.
45. Mannell A, Obers V. Pancreatic candidiasis. A case report. S Afr J Surg 1990;28:26-27.
46. Nikawa H, Hamada T, Yamamoto T. Denture plaque-past and recent concerns. J Dent 1998;26:299-304.
47. Cartledge JD, Midgely J, Gazzard BG. Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidiasis. J Clin Pathol 1997;50:477-480.
48. Graybill JR, Vazquez J, Darouiche RO, et al. Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. Am J Med 1998;104:33-39.
49. Phillips P, Zemcov J, Mahmood W, et al. Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility. AIDS 1996;10:1369-1376.
50. Porro GB, Parente F, Cernnschi M. The diagnosis of esophageal candidiasis in patients with acquired immune deficiency syndrome: is endoscopy always necessary? [see comments]. Am J Gastroenterol 1989;84:143-146.
51. Isaac DW, Parham DM, Patrick CC. The role of esophagoscopy in diagnosis and management of esophagitis in children with cancer. Med Pediatr Oncol 1997;28:299-303.
52. Lopez-Dupla M, Mora Sanz P, Pintado Garcia V, et al. Clinical, endoscopic, immunologic, and therapeutic aspects of oropharyngeal and esophageal candidiasis in HIV-infected patients: a survey of 114 cases. Am J Gastroenterology 1992;87:1771-1776.
53. Baehr PH, McDonald GB. Esophageal infections: risk factors, presentation, diagnosis, and treatment [see comments]. Castroenterology 1994;106:509-532.
54. Bonacini M, Young T, Laine L. The causes of esophageal symptoms in human immunodeficiency virus infection. A prospective study of 110 patients [see comments]. Arch Intern Med 1991;151:1567-1572.
55. Eichel M, Just-Nübling G, Helm EB, Stille W. [Itraconazole suspension in the treatment of HIV-infected patients with fluconazole-resistant oropharyngeal candidiasis and esophagitis.] Mycoses 1996;39(suppl 1):102-106.
56. Laine L, Conteas C, Islam MZ, DeBruin M. Multicenter study group. A prospective, randomized, double-blind trial of fluconazole vs. ketoconazole for Candida esophagitis: final results. Gasrroenterology 1991;100(5 pt. 2)A591.
57. Laine L, Dretler RH, Conteas CN, et al. Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS. A randomized trial [see comments]. Ann Intern Med 1992;117:655-660.
58. Moyer DV, Edwards JE Jr. Candida endophthalmitis and central nervous system infection. In: Bodey GP, cd. Candidiasis: pathogenesis, diagnosis and treatment, vol. 2. New York: Raven Press, 1993:331-355.
59. Brooks RG. Prospective study of Candida endophthalmitis in hospitalized patients with candidemia. Arch Intern Med 1989;149:2226-2228.
60. Edwards JE Jr, Foos RY, Montgomerie JZ, Guze LB. Ocular manifestations of Candida septicemia. Review of seventy-six cases of hematogenous Candida endophthalmitis. Medicine 1974;53:47-75.
61. Schrader W. [Endogenous Candida endophthalmitis. Early diagnosis and early vitrectomy improve the prognosis] Endogene Candidaendophthalmitis. Fruhzeitige Diagnose und fruhzeitige Vitrektomie verbessern die Prognose. Fortschr Ophthalmol 1990;87:331-335.
62. Barrie T. The place of elective vitrectomy in the management of patients with Candida endophthalmitis. Arch Clin Exp Ophthalmol 1987;225: 107-113.
63. Barza M. Treatment options for Candidal endophthalmitis [editorial; comment]. Clin Infect Dis 1998;27:1134-1136.
64. Benson WE. Vitrectomy. In: Duane TD, ed. Clinical ophthalmology, vol. 5. New York: Harper & Row, 1978.
65. Billson FA, Playfair TJ. The place for vitrectomy in posterior segment infection. Aust J Ophthalmol 1981;1:21.
66. Christmas NJ, Smiddy WE. Vitrectomy and systemic flnconazole for treatment of endogenous fungal endophthalmitis. Ophthal Surg leasers 1996;27:1012-1018.
67. Huang K. Vitrectomy in experimental endophthalmitis. Part I. Fungal infection. Ophthalmol Surg 1979;10:84.
68. Martínez-Vázquez C, Fernández-Ulloa J, Bordón J, et al. Candida albicans endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and followed by antifungal therapy [see comments]. Clin Infect Dis 1998;27:1130-1133.
69. Snip RC, Michels RG. Pars plana vitrectomy in the management of endogenous Candida endophthalmitis. Am J Ophthalmol 1976;82: 699.
70. Almekinders LC, Greene WB. Vertebral Candida infections. A case report and review of the literature. Clin Orthop 1991:174-178.
71. Gathe I, Harris RL, Garland B, et al. Candida osteomyelitis. Report of five cases and review of the literature. Am J Med 1987;82:927-937.
72. Lasday SD, Jay RM. Candida osteomyelitis. J Foot Ankle Stirg 1994;33:173-176.
73. Quindos G, Rowe IF, Higgens CS, et al. Candidal infection of bone. Assessment of serologic tests in diagnosis and management. Diagn Microbiol Infect Dis 1990;13:297-302.
74. Sugar AM, Saunders C, Diamond RD. Successful treatment of Candida osteomyelitis with fluconazole. A noncomparative study of two patients. Diagn Microbiol Infect Dis 1990; 13: 517-520.
75. Clancy CJ, Nguyen MH, Morris AJ. Candidal mediastinitis: an emerging clinical entity. Clin Infect Dis 1997;25:608-6B.
76. Anttila VJ, Ruutu P, Bondestam S, et al. Hepatosplenic yeast infection in patients with acute leukemia: a diagnostic problem. Clin Infect Dis 1994;18:979-981.
77. Blade J, Lopez-Guillermo A, Rozman C, et al. Chronic systemic candidiasis in acute leukemia. Ann Hematol 1992;64:240-244.
78. Loeliger A, van Leeuwen M, Rozenberg-Arska M, Dekker AW. Hepatosplenic candidiasis, a fatal disease? Infection 1992;20:336-338.
79. von Eiff M, Essink M, Roos N, et al. Hepatosplenic candidiasis, a late manifestation of Candida septicaemia in neutropenic patients with haematologic malignancies. Blut 1990;60: 242-248.
80. Walsh TJ, Whitcomb P, Piscitelli S, et al. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agent Chemotlier 1997;41:1944-1948.
81. Walsh TJ, Whitcomb PO, Revankar SG, Pizzo PA. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer 1995;76:2357-2362.
82. Flannery MT, Simmons DB, Saba II, et al. Fluconazole in the treatment of hepatosplenic candidiasis. Arch Intern Med 1992;152:406-408.
83. Jakab K, Kelemen E, Prinz G, Torok I. Amphotericin-resistant invasive hepatosplenic candidiasis controlled by fluconazole [letter; see comments]. Lancet 1990;335:473-474.
84. Kauffman CA, Bradley SF, Ross SC, Weber DR. Hepatosplenic candidiasis: successful treatment with fluconazole. Am J Med 1991;91:137-141.
85. Bayer AS, Edwards JE Jr, Seidel JS, Guze LB. Candida meningitis: report of seven cases and review of the English literature. Medicine 1976;55:477-486.
86. Buchs S, Pfister P. Candida meningitis: course, prognosis, and mortality before and after introduction of the new antimycotics. Mykosen 1982;26:73-81.
87. Chesney PJ, Justman RA, Bogdanowicz WM. Candida meningitis in newborn infants: a review and report of combined ampliotericin B-flucytosine therapy. Johns Hopkins Med J 1978;142: 155-160.
88. Chmel H. Candida albicans meningitis following lumbar puncture. Am J Med Sci 1973;266: 465-467.
89. Gelfand MS, McGee ZA, Kaiser AB, et al. Candidal meningitis following bacterial meningitis. South Med J 1990;83:567-570.
90. Lai PH, Lin SM, Pan HB, Yang CF. Disseminated miliary cerebral candidiasis. Am J Neuroradiol 1997;18:1303-1306.
91. Leggiadro RJ, Collins T. Postneurosurgical Candida lusitaniae meningitis. Fed Infect Dis J 1988;7:368-369.
92. Nguyen MH, Yu VL. Meningitis caused by Candida species: an emerging problem in neurosurgical patients. Clin Infect Dis 1995;21: 323-327.
93. Sarmienlo R, Holubka J, Khatib R Case report: Candida meningitis with an intradural filling defect 1 year after candidemia. Am J Med Sci 1994;307:115-118.
94. Sugerman B, Massanari M. Candida meningitis in patients with CSF shunts. Arch Neurol 1980;37:180-181.
95. Voice RA, Bradley SF, Sangeorzan JA, Kauffman CA. Chronic candidal meningitis: an uncommon manifestation of candidiasis. Clin Infect Dis 1994;19:60-66.
96. Ellis M. Fungal endocarditis. J Infect 1997;35: 99-103.
97. Galgiani JN, Stevens DA. Fungal endocarditis: need for guidelines in evaluating therapy. J Thorac Cardiovasc Surg 1977;73:293-296.
98. Johnston PG, Lee J, Domanski M, et al. Late recurrent Candida endocarditis. Chest 1991;99: 1531-1533.
99. McLeod R, Remington JS. Fungal endocarditis. In: Rahimtoola SH, ed. Infective endocarditis. New York: Grime and Stratton, 1978:211-290.
100. Merchant RK, Louria DB, Geisler PH, et al. Fungal endocarditis: review of the literature and report of three cases. Ann Intern Med 1958;48:242-266.
101. Moyer DV, Edwards JE Jr. Fungal endocarditis. In: Kaye D, ed. Infective endocarditis, vol. 2. New York: Raven Press, 1992:299-312.
102. Reyes MP, Lerner AM. Endocarditis caused by Candida species. In: Bodeg GP, Fainstein V, eds. Candidiasis. New York: Raven Press, 1985:203-209.
103. Seelig MS, Speth CP, Kozinn PJ, et al. Patterns of Candida endocarditis following cardiac surgery. Importance of early diagnosis and therapy (an analysis of 91 cases). Prog Cardiovasc Dis 1974;27:125-160.
104. Wilson HA Jr, Downes TR, Julian JS, et al. Candida endocarditis. A treatable form of pacemaker infection. Chest 1993;103:283-284.
105. Chim CS, Ho PL, Yuen ST, Yuen KV. Fungal endocarditis in bone marrow transplantation: case report and review of literature. J Infection 1998;37:287-291.
106. Canver CC, Patel AK, Kosolcharoen P, Voytovich MC. Fungal purulent constrictive pericarditis in a heart transplant patient. Ann Thorac Surg 1998;65:1792-1794.
107. Eng RHK, Sen P, Browne K, et al. Candida pericarditis. Am J Med 1981;70:867-890.
108. Rabinovici R, Szewczyk D, Ovadia P, et al. Candida pericarditis: clinical profile and treatment. Ann Thorac Surg 1997;63:1200-1204.
109. Schrank JH Jr, Dooley DP. Purulent pericarditis caused by Candida species: case report and review. Clin Infect Dis 1995;21:182-187.
110. Benoit D, Decruyenaere J, Vandewoude K. Management of candidal thrombophlebitis of the central veins: case report and review. Clin Infect Dis 1998;26:393-397.
111. Deitch EA, Marini JJ, Huseby JS. Suppurative Candida phlebitis of a peripheral vein. J Trauma 1980;20:618-620.
112. Hauser CJ, Bosco P, Davenport M, et al. Surgical management of fungal peripheral thrombophlebitis. Surgery 1989;105:510-514.
113. Garcia E, Granier I, Geissler A, et al. Surgical management of Candida stippurative thrombophlebitis of superior vena cava after central venous catheterization. Intensive Care Med 1997;23:1002-1004.
114. Torres-Rojas JR, Stratton CW, Sanders CV, et al. Candida suppurative peripheral thrombophlebitis. Ann Intern Med 1982;96:431-435.
115. Walsh TJ, Bustamente CI, Vlahov D, et al. Candidal suppurative peripheral thrombophlebitis: recognition, prevention, and management. Infect Contr 1986;7:16-22.
116. Khan EA, Correa AG, Baker CJ. Suppurative thrombophlebitis in children: a ten-year experience. Pediatr Infect Dis 1997;16:63-67.
117. Tornos P, Sanz E, Permanyer-Miralda G, et al. Late prosthetic valve endocarditis. Immediate and long-term prognosis. Chest 1992;101:37-41.
118. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999;340:764-771.